Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation Clinical Trial
Official title:
Effect of Roflumilast 500 μg Tablets Once Daily at Acute COPD Exacerbations Treated With Standard Therapy of Oral Steroids and Antibiotics. A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial
The purpose of this trial is to investigate if roflumilast can reduce the neutrophilic inflammation at acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). In addition, the potential benefit of roflumilast on severity and recovery periods of acute COPD exacerbations will be assessed using patient diaries and questionnaires.
Participants will be asked whether they agree to participate in the measurements of arterial
stiffness. Participants who agree will be included in the substudy, with the target of 60
patients with arterial stiffness measurements to complete the trial.
Study was terminated due to difficulty in identifying further eligible patients for this
exploratory study within a reasonable time.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02321215 -
Effectiveness and Feasibility of Delivering an Education Program to Patients With an Acute Exacerbation of COPD
|
N/A | |
| Completed |
NCT03458364 -
Comparison of HFNC With NIV in Weaning COPD
|
N/A |